The National Immunisation Schedule Update and Current issues

> Dr Brenda Corcoran National Immunisation Office





Objectives

- To outline immunisation schedules in Ireland
 - Primary childhood schedule
 - Vaccine uptake rates
 - School immunisation programme
 - Flu vaccination programme

To highlight development of new vaccines





Dates vaccines introduced into the Irish immunisation schedule

1937 - 1999			
Vaccine	Date introduced		
1. BCG	1937		
2. DT	1930s		
3. DTP	1952		
4. Oral Polio Vaccine (OPV)	1957		
5. Rubella	1971		
6. Measles	1985		
7. MMR	1988		
8. MMR2	1992		
9. Hib	1992		

2000 - 2016			
Vaccine	Date introduced		
1. Men C	2000		
2. DTaP-Hib-IPV (5 in1)	2001		
3. Inactivated Polio (IPV)	2001		
4. Hib Booster	2006		
5. Hepatitis B (as part of 6 in 1)	2008		
6. PCV7	2008		
7. HPV	2010		
8. PCV13	2010		
9. Tdap	2012		
10. Men C (adolescent booster)	2014		



Primary Childhood Immunisation (PCI) Schedule

2 months 6 in 1 + PCV
4 months 6 in 1 + Men C
6 months 6 in 1 + PCV (+MenC*)

12 months MMR + PCV13 months Men C + Hib

* if born before July 1st 2015




NEW Childhood Immunisation Schedule 2008 Information Pack



Reidhmeannacht na Seirhhíse Sláimte Health Service Executive




Vaccine uptake rate at 24 months 1999-2015








Quarter 4 2015 D3 immunisation uptake rates (%) by LHO, in those 24 months of age in Ireland and Dublin (source HPSC)







Quarter 4 2015 MMR immunisation uptake rates (%) by LHO, in those 24 months of age in Ireland and Dublin (source HPSC)








Decline in vaccine uptakes

Hib_bbooster dose by LHO in those reaching 24 months Q4 2015

	Q1 2010	Q3 2010	Q4 2015
Men C ₃	93%	80%	91%
PCV ₃	-	88%	93%
Hib _b (booster dose)	89%	84%	92%



Source: HPSC





Decline in vaccine uptakes

Actions

- Highlight 5 visits at every opportunity
- Give an appointment for next visit
- Send a text reminder before appointment
- Follow up defaulters as soon as possible
- Send vaccine returns on time
- Defaulters need appropriate vaccines even if they are over the recommended age






Primary Childhood Immunisation (PCI) Schedule

	CURRENT SCHEDULE		NEW SCHEDULE	
Date of birth	Babies born up to 30 th June 2015		s born up to 30 th June 2015 Babies born on or after 1st July 2015	
Age	Immunisations	Comment	Immunisations	Comment
2 months	6 in 1 + PCV	2 injections	6 in 1 + PCV	2 injections
4 months	6 in 1 + MenC	2 injections	6 in 1 + MenC	2 injections
6 months	6 in 1 + PCV + MenC	3 injections	6 in 1 + PCV	2 injections
12 months	MMR + PCV	2 injections	MMR + PCV	2 injections
13 months	MenC + Hib	2 injections	MenC + Hib	2 injections

- 6 in 1 Diphtheria, Tetanus, Pertussis, Polio, Hepatitis B, Haemophilus influenzae B
- PCV Pneumococcal conjugate vaccine
- MenC Meningococcal C vaccine
- MMR Measles, Mumps Rubella
- Hib Haemophilus influenzae B





Primary school immunisation schedule 2015/2016

Age (years)	Vaccine
4 -5	4 in 1
	MMR

- 4 in1 Diphtheria Tetanus Pertussis Polio
- MMR Measles, mumps and rubella








www.immunisation.ie

4 in 1 adverse events

More reactogenic

- hot, swollen, red and tender arms from the shoulder to elbow
- large, localised swelling (diameter > 50 mm) occurring around the injection site
- Begin within 48 hours of vaccination
- Resolve spontaneously
- Antibiotic treatment or anti-inflammatory not indicated
- Not usually associated with significant pain or limitation of movement
- Inform parents in advance







Primary school immunisation uptake 2011/12 - 2014/15 (Target 95%)








Second level school immunisation schedule 2015/2016

Age (years)	Vaccine
12-13	Tdap MenC*
12 – 13 (girls only)	HPV (2 dose schedule)

Tdap	Tetanus, Ic	ow dose	diphtheria	& pertussis

- MenC Meningococcal C vaccine
- HPV Human papillomavirus



Information for parents of children in First Year of second level school



	nation pro	0	-	000
Name:				
Date:				
Time of va	ccination:			
Your child	was given the follow	ing vaccines t	today	
	HPV		Tdap	MenC
 dizzine: headac Occasiona 	he	el sick or have	e a mild fever. On rare o	ccasions some children
			rofen to relieve aches a please seek medical ad	nd pains or to lower the vice.
The schoo	vaccination team c	in be contacti	ed during office hours f	rom Monday to Friday at
If you requ	ire medical advice a	fter these hou	urs please contact your	family doctor.
Before the	next vaccine, you sh	ould write to	the vaccination team i	f there has been
	is reaction to these v			
 any cha 	nge to your child's m	edical history	y or your consent	3
	t a record of your ch have all been comp			100
For more	information see		-	2
	immunisatio			





Feidhmeannacht na Seirbhíse Sláintí Health Service Brecutive


Adolescent MenC booster vaccine

- Peak rates in under 5 years and 15-19 years
- Concerns about waning immunity in adolescents
- Recent study
 - those vaccinated at <1 year, vaccine effectiveness decreased by 50% after 10 years
 - those vaccinated with one dose at 12–19 years showed no changes
 - vaccination at ≥12 years related to a low number of vaccine failures and a higher and longer protection over time
- MenACWY in UK since 2015/2016





Second level school immunisation uptake (Target 95%)








HPV vaccination programme

Gardasil (Sanofi Pasteur)

- protects against
 - HPV 16 and 18 (causes 70% cervical cancers) and
 - HPV 6 and 11 (causes 90% anogenital warts)



Computerised image of the human papillomavirus Courtesy of Dept of Pathology, University of Cambridge






HPV vaccine uptake 2010/2011 - 2014/2015 Routine programme First years





Over 80% (84.4%) uptake achieved for 3 dose schedule Excellent cohort retention >95% girls who started dose 1 completed dose 3





ARE HPV VACCINES SAFE?





Gardasil vaccine safety

- Over 200 million doses distributed worldwide
- Used in over 25 European countries, the US, Canada, Australia and New Zealand
- WHO, EMA, CDC repeatedly review safety data no serious adverse events

Nov 2015 EMA review found no evidence the vaccine was linked to chronic fatigue like conditions
Dec 2015 WHO concluded that Gardasil continues to have an excellent safety profile.
Jan 2016 European Commission endorsed the conclusion of the EMA, no need to change the licensed documentation






HPV vaccine safety May 2016

- 1015 reports to HPRA
 - consistent with the expected pattern of adverse effects for the vaccines
 - syncope (faints), gastrointestinal symptoms, malaise, headache
 - 2 reports of POTS (medically confirmed)
 - 2 reports of CRPS
 - 13 reports of chronic fatigue sysndrome
- 580,000 doses administered
- over 200,000 girls fully vaccinated





Known side effects of Gardasil



Very commonly (more than 1 in 10 patients):

 Pain, swelling and redness at injection site. Headache

Commonly (more than 1 in 100 patients):

 Bruising, itching at injection site, pain in extremity. Fever and nausea

Rarely (less than 1 in 1000 patients):

• Hives (urticaria)

Very rarely (less than 1 in 10,000 patients):

Syncope (vasovagal reaction), or fainting, Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash have been reported.

Patient Information Leaflet (PIL) at http://www.medicines.ie/medicine/11535/ PIL/ GARDASIL





HPV vaccine safety

"We have no evidence of a safety signal with the vaccine.

But what we do have is very clear evidence that this year 900 women, who have not received the vaccine, will die of cervical cancer, and the vaccine has the potential to prevent such deaths in future generations.

So the place of this vaccine in defending women's health is probably the most important thing we have ever done."

Professor Andrew Pollard Chair, JCVI, September 2015





CDC

CDC has carefully studied the risks of HPV vaccination.

HPV vaccination is recommended because the benefits, such as prevention of cancer, far outweigh the risks of possible side effects.

Benefits	Potential Risks
Cancer Prevention	Chance of fainting
Cervical, vaginal, and vulvar cancer in women Anal cancer in men and women	Pain, redness, or swelling in the arm where the shot was given
Likely penile cancer in men	
Likely oropharyngeal cancer in women and men	

http://www.cdc.gov/vaccinesafety/pdf/data-summary-hpv-gardasil-vaccine-is-safe.pdf





HPV vaccine impact in Australia High Grade Cervical Lesions <18 years




Figure 2: Incidence of high-grade cervical abnormalities, by age group

Incidence of high-grade cervical abnormalities (HGA; green dots) is the number of new diagnoses within a 3-month period per 100 women tested. Lowess smoothing trends are shown with red lines. The vertical lines, at the start of the second quarter in 2007, signify the introduction of human papillomavirus vaccination.



By 2013 reductions also seen in 20-24 year age group

Fieldhmeannacht na Seirthrise Släinte Health Service Executive

Brotherton et al Lancet 2011; 377: 2085–92

HPV vaccine effectiveness - Australia Genital warts


• Women <21years


- HPV vaccine 83% 1st dose uptake
- 2011
 - 93% decline in genital warts
 - no genital warts in vaccinated women

• Men

- 82% decline in genital warts in heterosexual men
- attributable to herd immunity

% Australian born diagnosed with genital warts by age group 2004 - 2011









More information



http://www.immunisation.ie/en/HealthcareProfessionals/ImmunisationGuidelines/



www.immunisation.ie

